TScan Therapeutics, Inc. (TCRX)

Over the past six months, TScan Therapeutics' stock has experienced various events and price movements. The stock price decreased by 8.18% over the last 12 months, and by 6.48% in the past month, though it saw a year-to-date return of 1.00% as of early April 2026. In December 2025, TScan announced positive updated data from the ALLOHA™ Phase 1 heme trial. In February 2026, the company completed enrollment in Cohort C of its Phase 1 ALLOHA™ trial and announced FDA clearance of Investigational New Drug applications for heme candidates TSC-102-A01 and TSC-102-A03 and participated in the TD Cowen 46th Annual Health Care Conference. In March 2026, TScan reported its Fourth Quarter and Full Year 2025 Financial Results and provided a business update and presented positive updated data from the ALLOHA™ Phase 1 heme trial. In April 2026, TScan participated in the 25th Annual Needham Virtual Healthcare Conference.

As a clinical-stage biopharmaceutical company, TScan Therapeutics does not currently have commercialized products or services, so there is no discernible demand seasonality for its products or services. Demand will be driven by clinical trial outcomes and eventual regulatory approvals, rather than seasonal factors.

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing T cell receptor-engineered T cell therapies for cancer patients. The company operates in the Healthcare sector, specifically in the Biotechnology and Medical - Biomedical and Genetics industries. TScan develops treatments by learning from patients who are successfully fighting cancer. TScan is building its ImmunoBank, a repository of therapeutic T cell receptors that recognize various targets and are associated with multiple human leukocyte antigen types. The company's major product candidates include TSC-100 and TSC-101 for hematologic malignancies, TSC-102-A01 and TSC-102-A03 targeting CD45, and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-205 for various solid tumors. TScan also applies its platform to identify unknown targets that cause T cell-driven autoimmune disorders.

TScan Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States. The company develops its T cell receptor-engineered T cell therapies for the treatment of patients with cancer in the United States.

TScan Therapeutics' brand reputation over the past year appears to be influenced by its clinical progress and analyst sentiment. The company has received a "Hold" consensus rating from analysts, with an average rating score of 2.33. Positive updated data from the ALLOHA™ Phase 1 heme trial, FDA clearance of Investigational New Drug applications, completion of enrollment in Cohort C of the Phase 1 ALLOHA™ trial, and increased revenue have likely contributed to its reputation.

TScan Therapeutics, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. Institutional shareholders hold 53.94% of the company, TScan Therapeutics insiders hold 29.91%, and retail investors hold 16.14%. Major institutional owners include Lynx1 Capital Management LP, BVF Inc/il, Baker Bros. Advisors Lp, Vanguard Group Inc, BlackRock, Inc., Standard Life Aberdeen plc, Deer Management Co. LLC, Renaissance Technologies Llc, Two Sigma Investments, Lp, and DC Funds, LP.